Julius Strauss, M.D.

Julius Strauss, M.D.

  • Center for Cancer Research
  • National Cancer Institute
Center for Immuno-Oncology


Dr. Strauss is a Staff Clinician (physician) in the Center for Immuno-Oncology (CIO). He is Clinical Director of CIO Combination Immunotherapy Group. His clinical research is focused on the use of novel agents capable of inducing the immune system to recognize and kill cancer cells. Dr. Strauss is very interested in the use of these agents in combination with each other as well as "standard" cytotoxic therapies in an effort to improve their efficacy. Dr. Strauss also has an interest in using these therapies to help patients with the fewest treatment options, including patients with rare diseases.

Areas of Expertise

1) immunotherapy 2) therapeutic cancer vaccines 3) immune checkpoint inhibitors

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them.


Selected Key Publications

Phase 1 trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in advanced solid tumors

Strauss J, Heery CR, Schlom J, Madan RA, Cao L, Kang Z, Lamping E, Marté JL, Donahue RN, Grenga I, Cordes L, Christensen O, Mahnke L, Helwig C, Gulley JL.
Clin Cancer Res.. 24: 1287-95, 2018.
Full-Text Article
[ Journal Article ]

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus–associated malignancies

Strauss J, Gatti-Mays M, Cho BC, Hil A, Salas S, McClay E, Redman J, Abdul Sater H, Donahue R, Jochems C, Lamping E, Burmeister A, Marté J, Cordes L, Bilusic M, Karzai F, Ojalvo L, Jehl G, Rolfe PA, Hinrichs CS, Madan R, Schlom J, Gulley JL
J ImmunoTher Cancer. 8(2): e001395, 2020.
Full-Text Article
[ Journal Article ]

First-in-human phase I trial of a tumor-targeted cytokine (NHS-IL12) in subjects with metastatic solid tumors

Strauss J, Heery CR, Kim J, Jochems C, Donahue RN, Montgomery AS, McMahon S, Lamping E, Marté JL, Madan RA, Bilusic M, Silver MR, Bertotti E, Schlom J, Gulley JL
Clin Cancer Res. 25(1): 99-109, 2019.
Full-Text Article
[ Journal Article ]

A phase I dose-escalation trial of BN-CV301, a recombinant poxviral vaccine targeting MUC1 and CEA with costimulatory molecules

Gatti-Mays ME, Strauss J, Donahue RN, Palena C, Del Rivero J, Redman J, Madan RA, Marté JN, Cordes L, Lamping E, Orpia A, Burmeister A, Wagner E, Pico Navarro C, Heery CR, Schlom J, Gulley JL
Clin Cancer Res. 25(16): 4933-4944, 2019.
Full-Text Article
[ Journal Article ]

A phase I trial using a multi-targeted recombinant Ad5 (CEA/MUC1/Brachyury)–based immunotherapy vaccine regimen in patients with advanced cancer

Gatti-Mays ME, Redman JM, Donahue RN, Palena C, Madan RA, Karzai F, Bilusic M, Sater HA, Marté JL, Cordes LM, McMahon S, Steinberg SM, Orpia A, Burmeister A, Schlom J, Gulley JL, Strauss J
Oncologist. 25(6): 479-e899, 2020.
Full-Text Article
[ Journal Article ]


Bonnie L. Casey
Patient Care Coordinator (Contr.)
Cynthia Moye
Patient Care Coordinator (Contr.)
Camilo Pacheco Puentes
Physician Assistant
Lauren Skeffington, M.S.